Information  X 
Enter a valid email address

Reckitt Benckiser Gp (RB.)

  Print          Annual reports

Tuesday 30 June, 2020

Reckitt Benckiser Gp

Director Declaration

RNS Number : 5978R
Reckitt Benckiser Group PLC
30 June 2020
 

30 June 2020

 

RECKITT BENCKISER GROUP PLC

 

Director Declaration

 

 

Reckitt Benckiser Group plc announces that Mary Harris, a Non-Executive Director of Reckitt Benckiser Group plc, has been appointed as a Supervisory Director of HAL Holding N.V., with effect from 30 June 2020.

 

This notification is made in accordance with Listing Rule 9.6.14 of the FCA's Listing Rules.

 

 

 

About RB

 

RB* is driven by its purpose to protect, heal and nurture in a relentless pursuit of a cleaner, healthier world. We fight to make access to the highest-quality hygiene, wellness and nourishment a right, not a privilege, for everyone.

 

RB is proud to have a stable of trusted household brands found in households in more than 190 countries. These include Enfamil, Nutramigen, Nurofen, Strepsils, Gaviscon, Mucinex, Durex, Scholl, Clearasil, Lysol, Dettol, Veet, Harpic, Cillit Bang, Mortein, Finish, Vanish, Calgon, Woolite, Air Wick and more.  20 million RB products a day are bought by consumers globally.

 

RB's passion to put consumers and people first, to seek out new opportunities, to strive for excellence in all that we do, and to build shared success with all our partners, while doing the right thing, always is what guides the work of our 40,000+ diverse and talented colleagues worldwide. For more information visit  www.rb.com

 

*RB is the trading name of the Reckitt Benckiser group of companies

 

Reckitt Benckiser Group plc's LEI code is 5493003JFSMOJG48V108

 

For further Information:
Rupert Bondy

Company Secretary

Tel +44 (0) 1753 217 800

 

John Dawson

SVP, Investor Relations

Tel. +44 (0) 1753 217 800

 

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
RDNFMMATMTIJBPM

a d v e r t i s e m e n t